ATE292641T1 - Mucin-mannan-konjugate und ihre immunotherapeutische anwendung - Google Patents

Mucin-mannan-konjugate und ihre immunotherapeutische anwendung

Info

Publication number
ATE292641T1
ATE292641T1 AT94303817T AT94303817T ATE292641T1 AT E292641 T1 ATE292641 T1 AT E292641T1 AT 94303817 T AT94303817 T AT 94303817T AT 94303817 T AT94303817 T AT 94303817T AT E292641 T1 ATE292641 T1 AT E292641T1
Authority
AT
Austria
Prior art keywords
conjugates
mucin
immunotherapeutic use
mannan conjugates
mannan
Prior art date
Application number
AT94303817T
Other languages
English (en)
Inventor
Ian Farquhar Mckenzie
Vasso Apostolopoulos
Geoff Allan Pietersz
Original Assignee
Ilexus Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ilexus Pty Ltd filed Critical Ilexus Pty Ltd
Application granted granted Critical
Publication of ATE292641T1 publication Critical patent/ATE292641T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94303817T 1993-12-24 1994-05-26 Mucin-mannan-konjugate und ihre immunotherapeutische anwendung ATE292641T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPM3223A AUPM322393A0 (en) 1993-12-24 1993-12-24 Mucin carbohydrate compounds and their use in immunotherapy

Publications (1)

Publication Number Publication Date
ATE292641T1 true ATE292641T1 (de) 2005-04-15

Family

ID=3777847

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94303817T ATE292641T1 (de) 1993-12-24 1994-05-26 Mucin-mannan-konjugate und ihre immunotherapeutische anwendung

Country Status (8)

Country Link
US (2) US5989552A (de)
EP (1) EP0659768B1 (de)
JP (2) JP3884088B2 (de)
AT (1) ATE292641T1 (de)
AU (1) AUPM322393A0 (de)
CA (1) CA2135833C (de)
DE (1) DE69434324T2 (de)
WO (1) WO1995018145A1 (de)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US8021667B2 (en) 1994-11-16 2011-09-20 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
CA2232501A1 (en) * 1995-09-18 1997-03-27 The Board Of Trustees Of The University Of Illinois An immunostimulant and antineoplastic glycan obtained from mycobacterium vaccae
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
ES2309992T3 (es) * 1995-10-20 2008-12-16 University Of Nebraska Board Of Regents Composiciones y procedimientos para incrementar las respuestas inmunes mediadas por celulas presentadoras de antigeno.
US20080286228A1 (en) * 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
EP0849275A1 (de) * 1996-09-26 1998-06-24 Rijksuniversiteit te Leiden Mannosylierte Peptide
AU5608798A (en) * 1996-12-20 1998-07-17 Merck & Co., Inc. Formulations of recombinant papillomavirus vaccines
CU22629A1 (es) * 1997-03-06 2000-12-22 Ct Ingenieria Genetica Biotech Formulaciones inmunopotenciadoras para uso vacunal
DE19740357A1 (de) * 1997-09-13 1999-03-18 Martin Wilhelm Phosphoryliertes Zuckermolekül
CA2304952C (en) 1997-09-29 2012-01-03 The Austin Research Institute Mannose-receptor bearing cells and antigen conjugate for immunotherapy
IL135148A0 (en) * 1997-10-03 2001-05-20 Galenica Pharmaceuticals Inc A polysaccharide conjugate and pharmaceutical compositions containing the same
EP1574217A1 (de) * 1997-10-03 2005-09-14 Galenica Pharmaceuticals, Inc. Iminbildende Polysaccharide, deren Herstellung und Verwendung als Zusatzmittel und Immunstimulierende Mittel
DE19758400A1 (de) * 1997-12-30 1999-07-01 Max Delbrueck Centrum Tumorvakzine für MUC1-positive Karzinome
US6562347B1 (en) * 1998-03-12 2003-05-13 The United States Of America As Represented By The Department Of Health And Human Services Chemokine-tumor antigen fusion proteins as cancer vaccines
EP1073667A2 (de) * 1998-04-28 2001-02-07 Galenica Pharmaceuticals, Inc. Polysaccharid-antigen-konjugate
SI1150712T1 (sl) 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
EP1046651A1 (de) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Zusammensetzungen und Verfahren zur Modulierung des interaktion zwischen dendritischer und T-zellen
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
AU780395B2 (en) * 2000-02-01 2005-03-17 Austin Research Institute, The Mucin-1 derived antigens and their use in immunotherapy
EP1257565A4 (de) * 2000-02-01 2005-04-06 Austin Research Inst Von mucin-1 abgeleitete antigene und ihre verwendung in der immuntherapie
US6956119B2 (en) * 2000-03-21 2005-10-18 Hans Loibner Polysaccharide-polypeptide conjugate
AU2001263653B2 (en) * 2000-06-06 2006-06-29 Igavax Pty Ltd Vaccine
AUPQ797700A0 (en) * 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
WO2002022686A2 (en) * 2000-09-15 2002-03-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
WO2002022687A2 (en) * 2000-09-15 2002-03-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Viral chemokine-tumur antigen fusion proteins
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
EP1585960A2 (de) * 2002-01-14 2005-10-19 Vertex Pharmaceuticals Incorporated Mucinimmobiliserte chromatographie
AU2003233008B2 (en) * 2002-04-22 2008-04-24 Recopharma Ab Fusion polypeptides and methods for inhibiting microbial adhesion
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
US20060142546A1 (en) * 2002-09-05 2006-06-29 Franz-Georg Hanisch Immunogenic muc1 glycopeptides
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
WO2012079878A2 (en) 2010-12-14 2012-06-21 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
PL1642905T3 (pl) 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
CN101175855A (zh) * 2005-01-28 2008-05-07 特拉维夫大学拉莫特有限公司 抗MUC1 α/β抗体
MX2007013725A (es) 2005-05-05 2008-04-09 Sensient Flavors Inc Produccion de beta-glucanos y mananos.
WO2007025282A2 (en) 2005-08-24 2007-03-01 Cedars-Sinai Medical Center Use of fructose-based compounds for the diagnosis of cancer
EP1760089B1 (de) 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe
ATE461215T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
GB2430881B (en) 2005-10-06 2010-10-13 Ntnu Technology Transfer As Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
US20090181041A1 (en) * 2006-01-23 2009-07-16 Jan Holgersson Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
AU2007208218A1 (en) * 2006-01-23 2007-08-02 Recopharma Ab Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
EP3011969A1 (de) * 2006-03-07 2016-04-27 Vaxinnate Corporation Zusammensetzungen mit hämagglutinin, verfahren zur herstellung und verfahren zur verwendung davon
US20080031872A1 (en) * 2006-08-02 2008-02-07 Karp Nelson M HIV immunogenic composition and method of administration
WO2008063982A2 (en) * 2006-11-13 2008-05-29 Procell Corp High mannose glycoprotein epitopes
GB0707096D0 (en) 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
KR101351195B1 (ko) 2007-07-27 2014-01-14 이매틱스 바이오테크놀로지스 게엠베하 면역 치료를 위한 새로운 면역원성 에피톱
HUE032379T2 (en) 2007-07-27 2017-09-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
RS54147B1 (sr) 2007-07-27 2015-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija protiv tumora mozga
US8501907B2 (en) 2007-08-10 2013-08-06 Janssen Biotech, Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
KR101588276B1 (ko) * 2007-08-10 2016-01-26 센토코 오르토 바이오테크 인코포레이티드 질환 표시자로서의 면역글로불린 절단 단편, 및 그의 검출 및 결합을 위한 조성물
CN101939030B (zh) 2007-11-27 2014-09-03 阿尔吉法玛公司 藻酸盐低聚物在抗击生物膜中的用途
ES2554981T3 (es) 2008-03-27 2015-12-28 Immatics Biotechnologies Gmbh Nueva inmunoterapia contra tumores neuronales y cerebrales
SI2113253T1 (sl) 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
PL2119726T5 (pl) 2008-05-14 2018-04-30 Immatics Biotechnologies Gmbh Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu
US20110236314A1 (en) 2008-09-12 2011-09-29 Cancer Research Initiatives Foundation Method of detection and diagnosis of oral and nasopharyngeal cancers
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
GB0904941D0 (en) 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
GB0904942D0 (en) 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
ES2442793T3 (es) 2009-06-03 2014-02-13 Algipharma As Tratamiento de Acinetobacter con oligómeros de alginato y antibióticos
EP2330122A1 (de) 2009-12-02 2011-06-08 Asklepios Kliniken Hamburg Gmbh OFA/iLRP-abgeleitetes modifiziertes Peptid
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201019331D0 (en) 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2011140595A2 (en) 2010-05-10 2011-11-17 4G Vaccines Pty Ltd Immunostimulatory and vaccine compositions
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
GB201015765D0 (en) 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
JP2014532799A (ja) 2011-11-09 2014-12-08 アセンド・バイオファーマシューティカルズ・リミテッド 免疫調節結合体
TWI714869B (zh) 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
US11203783B2 (en) 2013-11-21 2021-12-21 Repertoire Genesis Incorporation T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis
EP2883550A1 (de) 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Neuartige promiskuitive, HPV16-abgeleitete T-Helferepitope zur Immuntherapie
CN107108722A (zh) 2014-02-06 2017-08-29 医化学创药株式会社 针对粘蛋白4(muc4)糖肽的抗体及其用途
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
HRP20211754T1 (hr) 2014-12-23 2022-03-04 Immatics Biotechnologies Gmbh Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
DK3388075T5 (da) 2015-03-27 2024-09-23 Immatics Biotechnologies Gmbh Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
HRP20202019T1 (hr) 2015-07-01 2021-04-30 Immatics Biotechnologies Gmbh Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
MA51531A (fr) 2015-07-06 2020-11-11 Immatics Biotechnologies Gmbh Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
IL302705A (en) 2016-03-01 2023-07-01 Immatics Biotechnologies Gmbh Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
CR20180530A (es) 2016-04-06 2019-03-11 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia mieloide aguda (lma) y otros tipos de cancer
TW202304970A (zh) 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
WO2018138257A1 (en) 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
AU2018251839B2 (en) 2017-04-10 2022-06-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
EA201992416A1 (ru) 2017-04-10 2020-02-25 Имматикс Байотекнолоджиз Гмбх Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
TW201841934A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於治療癌症免疫治療的新穎肽及其肽組合物
US10800823B2 (en) 2017-07-07 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
EP4316597A3 (de) 2017-07-07 2024-11-06 immatics biotechnologies GmbH Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen lungenkrebs, einschliesslich nsclc, sclc und andere krebsarten
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
US20220332764A1 (en) 2019-08-29 2022-10-20 Eberhard Karls Universität Tübingen T cell epitopes of hcmv and uses of thereof
EP3892297A1 (de) 2020-04-09 2021-10-13 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptide und kombinationen von peptiden zur verwendung in der immuntherapie gegen eine infektion durch sars-cov-2 (covid-19)
EP3907284A1 (de) 2020-05-06 2021-11-10 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptide und kombinationen aus peptiden zur verwendung in der immuntherapie gegen hämatologische neoplasmen und andere krebsarten
EP3950705A1 (de) 2020-08-07 2022-02-09 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptide und kombinationen von peptiden zur verwendung in der immuntherapie gegen eine infektion durch sars-cov-2 (covid-19)
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
WO2022240741A1 (en) 2021-05-12 2022-11-17 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
JPWO2022270631A1 (de) 2021-06-25 2022-12-29
US20240316169A1 (en) 2021-07-05 2024-09-26 Regeneron Pharmaceuticals, Inc. Utilization of antibodies to shape antibody responses to an antigen
EP4198052A1 (de) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptide und antigenbindende proteine zur verwendung in der immuntherapie gegen fibrolamellares hepatozelluläres karzinom (fl-hcc) und andere krebsarten
EP4311834A1 (de) 2022-07-29 2024-01-31 Eberhard Karls Universität Tübingen, Medizinische Fakultät Peptide und kombinationen von peptiden zur verwendung in der immuntherapie gegen oropharyngeale plattenepithelkarzinome und andere krebsarten
EP4368189A1 (de) 2022-11-09 2024-05-15 Eberhard Karls Universität Tübingen, Medizinische Fakultät Peptide und kombinationen aus peptiden zur verwendung in der immuntherapie gegen akute myeloische leukämie (aml) und andere hämatologische neoplasmen
KR20250133922A (ko) 2023-01-12 2025-09-09 리제너론 파아마슈티컬스, 인크. TGFβ의 표적화된 전달을 위한 조성물 및 방법
WO2025040598A2 (en) 2023-08-18 2025-02-27 Immatics Biotechnologies Gmbh Peptides displayed by mhc for use in immunotherapy against different types of cancer
WO2025064470A1 (en) 2023-09-19 2025-03-27 Regeneron Pharmaceuticals, Inc. Viral peptides and uses thereof
WO2025136809A2 (en) 2023-12-19 2025-06-26 Regeneron Pharmaceuticals, Inc. Foxp3 peptides and uses thereof
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2279422A2 (fr) * 1974-07-22 1976-02-20 Inst Nat Sante Rech Med Forme pharmaceutique a base d'interferon
US4720386A (en) * 1976-11-24 1988-01-19 Mccollester Duncan L Vaccine and method for immunotherapy of neoplastic disease
US4415552A (en) * 1979-02-06 1983-11-15 The Governors Of The University Of Alberta Composition for establishing immunological tolerance
JPS5639022A (en) * 1979-09-05 1981-04-14 Hayashibara Biochem Lab Inc Preparation of vaccine
JPS57136528A (en) * 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
JPS61112023A (ja) * 1984-11-05 1986-05-30 Tanabe Seiyaku Co Ltd がん細胞傷害活性物質の新規製法
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
JP2594123B2 (ja) * 1987-09-12 1997-03-26 株式会社林原生物化学研究所 減感作剤
EP0326111A3 (de) * 1988-01-29 1989-12-27 New York Blood Center, Inc. Peptid-Derivate, immunogenisch gemacht bei Verabreichung zusammen mit Alaun als Zusatzmittel
US5047227A (en) * 1988-02-08 1991-09-10 Cytogen Corporation Novel and improved antibodies for site specific attachment of compounds
JP2849683B2 (ja) * 1988-03-11 1999-01-20 オオツカ アメリカ ファーマシューティカル、インコーポレーティッド 「動物及びヒトのムチンを用い、並びに合成炭水化物−担体結合物を用いた免疫による、ヒト癌関連抗原に対するモノクローナル抗体」
JPH01233219A (ja) * 1988-03-12 1989-09-19 Nippon Oil & Fats Co Ltd 制癌剤組成物
EP0338265B1 (de) * 1988-04-19 1994-05-04 American Cyanamid Company Haemophilus influenzae Typ B Polysaccharid-Aussermembranprotein-Konjugat als Impfstoff
AU620149B2 (en) * 1988-08-18 1992-02-13 Vaxine Pty Ltd Gamma inulin compositions
EP0442926A1 (de) * 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptide
ES2144414T3 (es) * 1990-12-20 2000-06-16 Arch Dev Corp The University O Control de la expresion de un gen por medio de una radiacion ionizante.
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
WO1993006858A1 (en) * 1991-10-09 1993-04-15 Dana Farber Cancer Institute, Inc. Lung cancer-associated protein
IL104382A0 (en) * 1992-01-17 1993-05-13 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant
JP3043888B2 (ja) * 1992-02-20 2000-05-22 森永乳業株式会社 グルコマンナン部分加水分解物を有効成分とする大腸ガン予防剤
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
AU3746293A (en) * 1992-03-06 1993-10-05 Biocine S.P.A. Conjugates formed from heat shock proteins and oligo- or polysaccharides
WO1994013312A1 (en) * 1992-12-15 1994-06-23 The Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression

Also Published As

Publication number Publication date
JP2007197419A (ja) 2007-08-09
EP0659768A3 (de) 1996-12-18
US6177256B1 (en) 2001-01-23
EP0659768A2 (de) 1995-06-28
JPH07206707A (ja) 1995-08-08
DE69434324D1 (de) 2005-05-12
DE69434324T2 (de) 2006-03-09
US5989552A (en) 1999-11-23
AUPM322393A0 (en) 1994-01-27
CA2135833C (en) 2008-09-09
WO1995018145A1 (en) 1995-07-06
EP0659768B1 (de) 2005-04-06
CA2135833A1 (en) 1995-06-25
JP4701146B2 (ja) 2011-06-15
JP3884088B2 (ja) 2007-02-21

Similar Documents

Publication Publication Date Title
ATE292641T1 (de) Mucin-mannan-konjugate und ihre immunotherapeutische anwendung
ATE475668T1 (de) Immunisierung durch impfung von dns transkriptionseinheit
ATE229978T1 (de) Helicobacter proteine und impstoffe
DE69030172D1 (de) Impfstoffe gegen Krebs und Infektionskrankheiten
FI953608A7 (fi) Rokoteyhdisteet ja menetelmä immuunireaktion aikaansaamiseksi limakalv ossa järjestelmällisellä rokottamisella
LU91486I2 (fr) Emulsion huile-dans-eau comprenant du squalène, duDL-a-tocophérol et du polysorbate 80
EP1181937A3 (de) Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans
EP1712628A3 (de) Verbindungen und Verfahren zur Immuntherapie und Diagnose von Tuberkulose
BR9610679A (pt) Antígenos de leishmania para uso na terapia e disgnose da leishmaniose
NL300403I1 (en) Method and manufacture of an acellular vaccine comprising Bordetella pertussis antigens
WO2000025815A8 (en) Novel immunoadjuvants
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
FI955150L (fi) OspC-antigeenirokotteiden immunogeenisia formulaatioita lyymisairauden ehkäisyyn ja hoitoon ja rekombinanttimenetelmiä antigeenien valmistamiseksi
AU4596397A (en) Rotavirus vaccine formulations
DE69018729D1 (de) Bildgebendes Gerät und Methode.
ATE134705T1 (de) Rekombinantes hyopneumoniae antigen und dessen verwendung
DE69029411D1 (de) Sicherheitsvorrichtung gegen einen Überdruck.
WO1998035045A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
FR2702655B1 (fr) Composition therapeutique nouvelle ayant un effet immunostimulant.
FR2708855B1 (fr) Compositions pharmaceutiques immunoadjuvantes ou immunostimulantes.
SE9600646D0 (sv) Vaccin
ITRM940133A0 (it) Dispositivo riscaldatore e sterilizzatore rapido ad induzione elettromagnetica di alta frequenza, per attrezzi di odontotecnica odontoiatria, microchirurgica, estetica e simili.
SI0701612T1 (en) IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties